Projects per year
Abstract
Aims: Several studies have shown that heart failure (HF) drug treatment seems to benefit patients with preserved ejection fraction (HFpEF) and a left ventricular ejection fraction (LVEF) up to 55–60% but not with higher LVEF. Certain HF drugs are now indicated in patients with HFpEF and a LVEF below normal. However, not much is known about patients with a normal LVEF. Therefore, we investigated the prevalence, clinical characteristics and outcome of patients with HF and a normal LVEF.
Methods and results: Normal LVEF was defined according to the Recommendations for Cardiac Chamber Quantification from the American Society of Echocardiography as a LVEF ≥62% for men and ≥ 64% for women. Preserved ejection fraction was defined as a LVEF ≥50% and reduced ejection fraction as a LVEF <50%. In the total cohort of 1568 studied patients with heart failure (mean age 73 years; 33.6% female) 57 patients (3.6%) had a normal LVEF. These patients least likely had a previous myocardial infarction (p < 0.001) or diabetes (p = 0.045), had the lowest Left Ventricular End Diastolic Diameter (p < 0.001), the highest rate of previous HF hospitalization in the last year (p = 0.015), the highest cardiac output (p < 0.001) and were most frequently women (p < 0.001). Patients with a normal LVEF had the lowest risk for the primary combined outcome of all-cause mortality and HF hospitalization.
Conclusion: Only 3.6% of patients with HF had a sex-adjusted normal LVEF. Despite the sex-adjusted cut-offs they were more frequently female with less ischemic heart disease, higher cardiac output and better clinical outcomes.
Original language | English |
---|---|
Pages (from-to) | 85-90 |
Number of pages | 6 |
Journal | International Journal of Cardiology |
Volume | 364 |
Early online date | 29 May 2022 |
DOIs | |
Publication status | Published - Oct 2022 |
Keywords
- Heart failure
- Women
- LVEF
- Normal LVEF
- BIOSTAT-CHF
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'Heart failure with normal LVEF in BIOSTAT-CHF'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Aref#d: 21596. BIOSTAT-CHF: A Systems Biology Study to Tailored Treatment in Chronic Heart Failure
Doney, A. (Investigator), Guthrie, B. (Investigator), Lang, C. (Investigator), Morris, A. (Investigator), Palmer, C. (Investigator) & Struthers, A. (Investigator)
COMMISSION OF THE EUROPEAN COMMUNITIES
1/04/10 → 31/03/15
Project: Research